Hepatitis C Nucleos(t)ide Analog NS5B Polymerase Inhibitors

Hepatitis C nucleos(t)ide analog NS5B polymerase inhibitors are a therapeutic class of direct-acting antiviral agents utilized primarily for the management and cure of chronic hepatitis C virus infection

Hepatitis C nucleos(t)ide analog NS5B polymerase inhibitors are a therapeutic class of direct-acting antiviral agents utilized primarily for the management and cure of chronic hepatitis C virus infection Administered as prodrugs, these agents are intracellularly converted into pharmacologically active triphosphate forms that mimic natural nucleotides and bind directly to the conserved catalytic active site of the viral RNA-dependent RNA polymerase By competing with physiological substrates, they...

Administered as prodrugs, these agents are intracellularly converted into pharmacologically active triphosphate forms that mimic natural nucleotides and bind directly to the conserved catalytic active site of the viral RNA-dependent RNA polymerase Because their target site is highly conserved across viral genotypes, members of this class typically display pangenotypic antiviral activity and a high genetic barrier to resistance

Administered as prodrugs, these agents are intracellularly converted into pharmacologically active triphosphate forms that mimic natural nucleotides and bind directly to the conserved catalytic active site of the viral RNA-dependent RNA polymerase By competing with physiological substrates, they induce premature viral RNA chain termination, thereby halting viral replication

Because their target site is highly conserved across viral genotypes, members of this class typically display pangenotypic antiviral activity and a high genetic barrier to resistance